A STUDY TO ASSESS CHANGE IN CONTRAST SENSITIVITY AND VISUAL ACUITY IN PROLIFERATIVE DIABETIC RETINOPATHY PATIENTS UNDERGOING ANTI-VEGF TREATMENT AND ROLE OF LOW VISION AID IN SUCH PATIENTS

VISHAL YADAV; LALIT SACHDEVA; ANIL KUMAR SRIVASTAVA; PRASHANT BHUSHAN

doi:10.22159/ajpcr.2023.v16i12.48537

Authors

VISHAL YADAV Department of Ophthalmology, Mayo Institute of Medical Sciences, Barabanki, Uttar Pradesh, India. https://orcid.org/0009-0005-8492-0123
LALIT SACHDEVA Department of Ophthalmology, Mayo Institute of Medical Sciences, Barabanki, Uttar Pradesh, India.
ANIL KUMAR SRIVASTAVA Department of Ophthalmology, Mayo Institute of Medical Sciences, Barabanki, Uttar Pradesh, India.
PRASHANT BHUSHAN Department of Ophthalmology, RIO BHU, Varanasi, Uttar Pradesh, India.

DOI:

https://doi.org/10.22159/ajpcr.2023.v16i12.48537

Keywords:

Diabetic retinopathy, Visual acuity, Contrast sensitivity, Anti-vascular endothelial growth factor injections

Abstract

Objective: The aim of this study was to study the effect of intravitreal anti-vascular endothelial growth factor (VEGF) on the visual acuity (VA) using logMAR charts and the contrast sensitivity (CS) using the pelli-robson chart in patients of advanced diabetic retinopathy.

Design: We performed a retrospective study to assess the change in CS and VA in diabetic retinopathy (DR) with or without proliferative DR patients receiving intra-vitreal anti VEGF.

Methods: The study was done at our institution where 40 patients of DR were included in the study, 20 cases (20 eyes) and 20 controls (20 eyes). Moreover, it comes under the criteria of low vision and above 18 years of age and VA >6/60. VA and CS were compared before injection and after injection at 14 days, 30 days, and 90 days, respectively.

Results: On comparing the mean of CS change before injections and after injections at 14 days (p=0.036), 30 days (p=0.012), and 90 days (p=0.012), respectively, showed a significant association between change in CS change within group but on comparing with control group at 14 days (p=0.195), 30 days (p=0.247), 90 days (p=0.247), respectively, showed no significant association. Another comparison of mean VA before injection and after injection in the case group at 14 days, 30 days, and 90 days, respectively, (p=0.329) remains the same. Which is insignificant but on comparison with the control group (p=0.02) showed a significant association.

Conclusion: Whatever VA and CS are achieved with anti-VEGF was completed at 14 days of injection.

Downloads

Download data is not yet available.

References

Wong TY, Cheung CM, Larsen M, Sharma S, Simó R. Diabetic retinopathy. Nat Rev Dis Primers 2016;2:16012. doi: 10.1038/ nrdp.2016.12, PMID 27159554

Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53. doi: 10.2337/diacare.27.5.1047, PMID 15111519

Prevention of blindness from diabetic retinopathy. Report of a WHO consultation. Geneva: WHO; 2005.

Guidelines for the Comprehensive Management of Diabetic Retinopathy in India. A Vision 2020 the Right to Sight India Publication; 2008.

Kempen JH, O’Colmain BJ, Leske MC, Haffner SM, Klein R, MossSE, et al. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol 2004;122:552-63. doi: 10.1001/ archopht.122.4.552, PMID 15078674

Narayan KM, Boyle JP, Geiss LS, Saaddine JB, Thompson TJ. Impact of recent increase in incidence on future diabetes burden: U.S., 2005- 2050. Diabetes Care 2006;29:2114-6.

King H, Aubert RE, Herman WH. Global burden of diabetes, 1995- 2025: Prevalence, numerical estimates, and projections. Diabetes Care 1998;21:1414-31.

Zhang X, Saaddine JB, Chou CF, Cotch MF, Cheng YJ, Geiss LS, et al. Prevalence of diabetic retinopathy in the United States, 2005-2008. JAMA 2010;304:649-56. doi: 10.1001/jama.2010.1111, PMID 20699456

Marmor MF. Contrast sensitivity versus visual acuity in retinal disease. Br J Ophthalmol 1986;70:553-9. doi: 10.1136/bjo.70.7.553, PMID 3487345

Arden GB. The importance of measuring contrast sensitivity in cases of visual disturbance. Br J Ophthalmol 1978;62:198-209. doi: 10.1136/ bjo.62.4.198, PMID 348230

Sokol S, Moskowitz A, Skarf B, Evans R, Molitch M, Senior B. Contrast sensitivity in diabetics with and without Background retinopathy. Arch Ophthalmol 1985;103:51-4. doi: 10.1001/ archopht.1985.01050010055018, PMID 3977675

Howes SC, Caelli T, Mitchell P. Contrast sensitivity in diabetics with retinopathy and cataract. Aust J Ophthalmol 1982;10;173-8.

Preti RC, Ramirez LMV, Monteiro MLR, Carra MK, Pelayes DE, Takahashi WY. Contrast sensitivity evaluation in high risk proliferative diabetic retinopathy treated with panretinal photocoagulation associated or not with intravitreal bevacizumab injections: A randomised clinical trial. Br J Ophthalmol 2013;97:885-9.